ASCO '15: J&J Antibody Benefits Patients With Hardest-to-Treat Multiple Myeloma

CHICAGO (TheStreet) -- Patients with multiple myeloma no longer responding to currently approved drugs benefited from treatment with an experimental monoclonal antibody developed by Johnson & Johnson (JNJ), according to new study results unveiled Saturday at the American Society of Clinical Oncology (ASCO) annual meeting.

Nearly 1 in 3 heavily pre-treated multiple myeloma patients responded to the J&J drug, known as daratumumab. Disease progression was delayed by almost four months, on average.

J&J intends to seek approval for daratumumab later this year. The U.S. Food and Drug Administration has already granted daratumumab Breakthrough Therapy Designation status.

Daratumumab is a monoclonal antibody that binds to proteins known as CD38 found on the surface of myeloma cells. Such antibodies as Roche's Rituxan are a core treatment in other blood cancers, like non-Hodgkin's lymphoma, but this class of drug has never before been developed against myeloma.

The phase II study enrolled 106 patients with multiple myeloma no longer responding to a minimum of three approved therapies. Many patients had already cycled through five treatments, including Revlimid, Velcade, Pomalyst and Kyprolis. All the patients were treated with infusions of daratumumab and followed for response.

After a median followup of 9.4 months, 29% of patients responded to daratumumab, with three patients experiencing a complete remission. On average, responses to daratumumab lasted 7.4 months. The median time to disease progression was 3.7 months and 65% of enrolled patients were alive at one year.

Infusion-related reactions were reported by 43% of patients in the study, mostly mild to moderate in severity. No patient discontinued from the study due to infusion-related reactions. Other side effects reported included fatigue, anemia and nausea.

Study results from another monoclonal antibody in multiple myeloma, developed by Bristol-Myers Squibb (BMY) and Abbvie  (ABBV), were previously reported.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Some of Trump's NFL Owner Friends Side With Players in Dispute With President

The Best Companies for Women

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'